-
September 9, 2020
What’s New in Treatment for Castrate-Resistant Prostate Cancer?
Emma Shtivelman, PhDAbout 10% to 20% of all prostate cancers are classified as castrate-resistant prostate cancer (CRPC). CRPC occurs when prostate cancer evolves to resist standard treatment with androgen deprivation therapy (ADT), which blocks the production and signaling activity of hormones called androgens (such as testosterone) that fuel the cancer’s growth. Most CRPCs are diagnosed as metastatic (mCRPC), meaning they have already… Read more »
-
December 3, 2020
Olaparib Granted Positive EU Opinion for BRCA1/2+ Advanced Prostate CancerBookmark
George Lundberg, MDA news story published by OncLive reports that the European Union’s Committee for Medicinal Products for Human Use recently approved the drug olaparib for treating patients with a subset of advanced castrate-resistant prostate cancers that have BRCA1/2 mutations.
.
-
November 24, 2020
Two New Treatments Approved For Advanced Prostate CancerBookmark
George Lundberg, MDA story published by the Prostate Cancer Foundation outlines two new treatment options approved by the U.S. Food and Drug Administration (FDA) this year. The two medications, rucaparib and olaparib, each target specific mutations that may be found in a patient’s tumor, and each was approved for a specific type of prostate cancer.
.
-
August 15, 2020
NCCN Clinical Practice Guidelines in Oncology: 2020 UpdatesBookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
The National Comprehensive Cancer Network (NCCN) recently made key updates to its clinical practice guidelines. This news story provides a summary of the updates.
Go to full news story published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 7, 2020
FDA Approves Merck’s Keytruda, Foundation Medicine CDx for TMB-High Solid TumorsBookmark
George Lundberg, MDArticle from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.
Go to full article published by GenomeWeb.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 15, 2019
Prostate Cancer—An OverviewBookmark
George Lundberg, MDCurated by Editor in Chief George Lundberg, MD, who notes:
Prostate cancer is the most common potentially lethal cancer diagnosed among American men. The great majority do not die of their disease. But there are many controversies about best handling. To learn more, read this authoritative, detailed presentation from Medscape, published August 2019.
.
Show More

E. David Crawford, MD
Cancer Commons Advisor
-
October 8, 2018
Accuracy and Precision Define Radiation Oncology
With:A Q&A with Eddy Yang, MD, PhD, Professor and Vice Chair of Translational Sciences Department of Radiation Oncology; Deputy Director, Associate Director of Precision Oncology at the Hugh Kaul Precision Medicine Institute; Birmingham, AL; shyang@uabmc.edu Originally published December 5, 2017 Q: You are a radiation oncologist with a particular interest in cancer of the prostate. How does the molecular study… Read more »
-
February 11, 2020
Carcinoma of Unknown Primary Case Reviewed in Tumor Board SessionBookmark
George Lundberg, MDArticle from CAP Today curated by Editor in Chief George Lundberg, MD, who notes:
Tumor boards are an established method of dealing with problem cancer cases. In precision oncology, they may, even must, be molecular. This is a great example of how a molecular tumor board can provide actionable insights for patients.
Go to full article published by CAP Today.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
February 7, 2017
Testing for Tumor Mutations: Liquid Biopsy Versus Traditional Biopsy
Emma Shtivelman, PhDUpdate as of August 27, 2020: A lot has changed in the three-and-a-half years since this blog post was written. Liquid biopsies are by now widely recognized and used as a valuable diagnostic and monitoring tool. Many of the reservations and concerns described in the original post below have been addressed and largely resolved by refining the technology. The latest… Read more »
Show More
Some of the most promising new treatments for metastatic prostate cancer are currently being tested in patients enrolled in clinical trials. We help you stay up to date on the latest results from these studies.
-
March 7, 2019
Targeted Radiation Therapy Yields High Response Rates in Metastatic Prostate CancerBookmark
Emma Shtivelman, PhDExcerpt:
“The targeted radiation therapy Lutetium-177 PSMA-617 produced high response rates among men with prostate-specific membrane antigen-positive metastatic, castration-resistant prostate cancer, according to results of a single-arm, phase 2 trial scheduled for presentation at Genitourinary Cancers Symposium.
“The treatment also appeared well-tolerated among these men, whose disease had progressed after multiple standard therapies.”
Go to full article published by Healio on Feb 14, 2019.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
October 22, 2018
The Link Between Apalutamide and QOL in Non-Metastatic CRPCBookmark
Emma Shtivelman, PhDExcerpt:
“Adding apalutamide to androgen deprivation therapy (ADT) does not appear to harm health-related quality of life (HRQOL) in men with nonmetastatic castration-resistant prostate cancer (CRPC), according to new research published in Lancet Oncology.
“Previous research has showed that men in this patient population who received apalutamide had longer metastasis-free survival and a longer time to symptomatic progression compared with those who received placebo. This new study found that adding apalutamide still preserves HRQOL. Specifically, the group mean patient-reported outcome scores over time demonstrated HRQOL was maintained from baseline (initiation of apalutamide), and it was similar over time among men receiving apalutamide versus placebo.”
Go to full article published by Cancer Network on Oct 9, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
September 25, 2018
Apalutamide Maintains Health-Related QoL in Nonmetastatic CRPCBookmark
Emma Shtivelman, PhDExcerpt from OncLive:
“Treatment with apalutamide (Erleada) was not associated with a significant impact on health-related quality of life (HRQoL) in patients with high-risk nonmetastatic castration-resistant prostate cancer, according to patient-reported outcome (PRO) data from the phase III SPARTAN trial.
“In the study overall, patients treated with the addition of apalutamide to standard hormone therapy also had an improvement in metastasis-free survival (MFS) and longer time to symptomatic progression compared with those who were treated with placebo.”
Go to full article published by OncLive on Sep 17, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
August 22, 2018
Combo Tx No Help After PSA Progression in mCRPCBookmark
Emma Shtivelman, PhDExcerpt from MedPage Today:
“Adding abiraterone acetate (Zytiga) to enzalutamide (Xtandi) did not improve progression-free survival (PFS) after prostate-specific antigen (PSA) progression in men on enzalutamide monotherapy for chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), researchers found.
“In the randomized, double-blind PLATO trial, the median PFS in patients treated with enzalutamide plus abiraterone and prednisone was 5.7 months. By comparison, the PFS was 5.6 months in the control group treated with abiraterone and prednisone plus placebo (hazard ratio [HR] 0.83; P=0.22).”
Go to full article published by MedPage Today on July 28, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
Show More

E. David Crawford, MD
Cancer Commons Advisor
Cancer affects many aspects of life, whether you’re newly diagnosed, in the midst of treatment, or in follow-up care. Learn about ways to maintain quality of life, such as palliative care and managing side effects.
-
October 14, 2019
Pediatric Palliative Care: A Specialty Comes of Age
For a child with cancer, palliative care can provide much-needed relief from stress and symptoms—for the patient and their family alike. Palliative care is given alongside cancer treatment, and is not synonymous with “end-of-life” care. In fact, anyone with a serious illness can benefit from palliative care, no matter their long-term outlook. Because of its importance for children with cancer,… Read more »
-
February 11, 2020
‘Impressed With Impact’ of Ketamine in Cancer Palliative CareBookmark
George Lundberg, MDArticle from Medscape curated by Editor in Chief George Lundberg, MD, who notes:
Depression is, for obvious reasons, common in patients with advanced cancer. The old, inexpensive drug ketamine—already approved for medical use by the U.S. Food and Drug Administration (FDA)—seems rapidly effective, according to small studies.
Go to full article published by Medscape.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
October 7, 2019
Emphasizing Oncogeriatrics
With:A Q&A with Nicolò Matteo Luca Battisti, MD, Medical Oncologist at The Royal Marsden NHS Foundation Trust, London, United Kingdom, and Chair of the Young Interest Group of the International Society of Geriatric Oncology (SIOG); nicolo.battisti@gmail.com Q: Everyone knows that the practice of pediatric oncology is very different from adult oncology. How does the growing field of oncogeriatrics differ from… Read more »
-
December 3, 2018
Best Uses of Physical Medicine and Rehabilitation in Patients with Cancer
With:A Q&A with Val Jones, MD, Medical Director of Admissions, Saint Luke’s Rehabilitation Institute, Spokane, WA Originally published February 1, 2017 Q: Your principal practice in Spokane, Washington is physical medicine and rehabilitation (PM&R). What do you find to be the best uses of PM&R in patients with cancer at your facility? A: Rehabilitation medicine is one of the best-kept secrets… Read more »
-
September 14, 2018
Huge Progress in Palliative Care
With:A Q&A with Diane E. Meier, MD, FACP, Director, Center to Advance Palliative Care; Professor of Geriatrics and Palliative Medicine, Icahn School of Medicine at Mount Sinai; New York, NY; diane.meier@mssm.edu Originally published November 8, 2017 Q: You wrote in MedGenMed in 2007 that palliative care was the job of all hospitals. In October 2017 you were honored at the National… Read more »
-
July 23, 2018
Cancer Pain and the Opioid Epidemic
George Lundberg, MDA Q&A with Kevin Sevarino, MD, PhD, President-elect of the American Academy of Addiction Psychiatry and Consulting Psychiatrist at Gaylord Hospital in Wallingford, CT Q: Opioid abuse, addiction, and overdose are huge American problems right now. Many cancer patents experience chronic pain. What is the best way to use opioids to manage chronic pain? [Note: The views expressed below represent the… Read more »
Show More
Learn more about what’s new in advanced cancer research and treatment, including screening and statistics, using artificial intelligence to improve treatment, and other new horizons in cancer care.
-
November 10, 2020
How to Learn About Cancer in a Classroom: Shaping Compassionate Doctors
With:The patients and caregivers we serve here at Cancer Commons rely on their doctors to provide expert, compassionate care. Building the skills to give such care can begin early in a doctor’s education. Here, for a change of pace, our Curious Dr. George asks a future doctor about a unique experience that helped her learn how to connect with cancer… Read more »
-
September 9, 2020
Is Cancer the Best Way to Die?
With:In 2014, the prestigious medical research journal The BMJ published a controversial piece called “Dying of cancer is the best death.” Here, our Curious Dr. George asks the author of that piece, Richard Smith, CBE, FMedSci, if and how his thoughts on death have since evolved. Dr. Smith was Editor of The BMJ from 1991 to 2004 and is currently Chair… Read more »
-
August 21, 2020
The Power of Precision Medicine is Exemplified by Tempus
With:Tempus—a tech company & partner of Cancer Commons—empowers doctors to make data-driven decisions for their patients in real time. Learn how.
-
June 29, 2020
Cancer Screening Programs Influence Incidence and Causes of Cancer DeathsBookmark
Lola Rahib, PhDArticle from ASCO Daily News curated by Director of Scientific and Clinical Affairs, Lola Rahib, PhD.
In collaboration with MD Anderson Cancer Center and the Pancreatic Cancer Action Network, Cancer Commons presented new research at the American Society of Clinical Oncology (ASCO)’s virtual 2020 meeting. The findings show that, by 2040, we will likely see notable changes in which cancer types are most common and which are most deadly, highlighting the influence of cancer screening programs. This research was led by Dr. Rahib at Cancer Commons.
Go to full article published by ASCO Daily News.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
May 30, 2020
What Have I Learned in More Than Half a Century in Cancer Medicine?Bookmark
George Lundberg, MDArticle from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes:
“Patients with cancer need to be embraced with love and compassion. They need caring beyond medicine.”Go to full article published by The ASCO Post.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
-
April 27, 2020
The Challenges of Using Artificial Intelligence to Improve Cancer Treatment
With: Razelle Kurzrock, MDJeff Shrager, PhDIn a previous post, CureMatch co-founder Razelle Kurzrock, MD, told us all about her company’s artificial intelligence (AI) platform that matches patients with treatments based on their cancer’s molecular profile. Here, AI expert Jeff Shrager, PhD, responds, and Kurzrock offers a rebuttal. Shrager is Co-Founder and Director of Research at xCures, and was formerly Director of Research at Cancer Commons.… Read more »
Show More
The coronavirus pandemic presents unprecedented challenges to cancer patients. We can help you understand how COVID-19 might impact your treatment and other aspects of your cancer care.
-
June 10, 2020
How I Cope with the Tsunami of Cancer and COVID-19 Info
With: Kevin Knopf, MD, MPHOncologists worldwide face the challenge of staying on top of the latest treatments, research findings, and other information that could help them treat their patients more effectively. Now, they must do so in the context of COVID-19. Here, our Curious Dr. George asks Kevin Knopf, MD, MPH, Division Chief of Hematology/Oncology at Highland Hospital/Alameda Health Systems in Oakland, California, how… Read more »
-
February 20, 2021
COVID-19 Vaccination: The VOICE for Patients with CancerBookmark
George Lundberg, MDThis piece from the scientific journal Nature Medicine describes a new clinical trial studying vaccination against COVID-19 specifically in patients with cancer.
.
-
February 20, 2021
Patients with Cancer Less Likely to Enroll in Clinical Trials Due to COVID-19Bookmark
George Lundberg, MDFewer patients with cancer may be willing to enter a clinical trial. This Cancer Network article explains why and offers solutions.
.
-
February 20, 2021
NCI-Supported Clinical Trials for CoronavirusBookmark
George Lundberg, MDThis list from the National Cancer Institute outlines many government-supported clinical trials for COVID-19 that may be specifically for cancer survivors.
.
-
February 20, 2021
What Cancer Survivorship Can Teach Us About COVID-19Bookmark
George Lundberg, MDCancer survivors and (especially long) COVID-19 survivors may have a lot in common, as outlined in this opinion piece from STAT.
.
-
August 7, 2020
Clinical Trials Gone VirtualBookmark
George Lundberg, MDArticle from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes:
During the COVID-19 pandemic, some clinical trials have gone virtual.
Go to full article published by GenomeWeb.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.
Show More